Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Levy on the Future of Atezolizumab in NSCLC

November 11th 2022

Benjamin Philip Levy, MD, discusses potential future uses for atezolizumab in non–small cell lung cancer.

Pembrolizumab/Eftilagimod alpha Combo Shows Durable Responses in Frontline NSCLC

November 11th 2022

The first-line combination of pembrolizumab and eftilagimod alpha elicited a 40.4% (95% CI, 31.3%-50.0%) overall response rate by immune RECIST criteria in the intent-to-treat population in patients with advanced non–small cell lung cancer, according to updated findings from the phase 2 TACTI-002 trial.

Dr. Halmos on the FDA Approval of Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC

November 11th 2022

Balazs Halmos, MD, discusses the significance of the FDA approval of tremelimumab-actl plus durvalumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Kris on Atezolizumab in NSCLC

November 10th 2022

Mark G. Kris, MD, discusses the role of atezolizumab in patients with non–small cell lung cancer.

FDA Approves Tremelimumab Plus Durvalumab and Chemo for Metastatic NSCLC

November 10th 2022

The FDA has approved tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

The Future of Molecular Testing in NSCLC

November 9th 2022

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Financial Considerations with Molecular Testing for Patients With NSCLC

November 9th 2022

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.

The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

November 9th 2022

Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.

Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

November 9th 2022

Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.

Exciting NSCLC Data Updates from ESMO 2022

November 9th 2022

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

FDA Approves Cemiplimab-rwlc Plus Platinum-based Chemotherapy for Advanced NSCLC

November 8th 2022

The FDA has approved cemiplimab-rwlc (Libtayo) in combination with platinum-based chemotherapy in adult patients with advanced non–small cell lung cancer with no EGFR, ALK, or ROS1 aberrations.

Investigators Highlight Top Advances at ESMO 2022

November 7th 2022

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

KEYNOTE-189 Analysis Supports Pembrolizumab/Chemo as a Frontline Standard in Metastatic NSCLC

November 4th 2022

Five-year follow-up data from the phase 3 KEYNOTE-189 trial further confirms the use of first-line pembrolizumab in combination with pemetrexed and platinum improves long-term survival outcomes for patients with treatment-naïve, metastatic, nonsquamous non–small cell lung cancer.

The Evolving Treatment Landscape in Relapsed/ Refractory Follicular Lymphoma

November 4th 2022

On September 8, 2022, OncLive® brought together physicians who treat FL to participate in a virtual workshop and discuss the treatment landscape and management of patients with relapsed/refractory (R/R) FL. The discussion was led by Krish Patel, MD; perspectives and insights on current treatment options, trial data, and other novel therapies were exchanged.

Exploring the Role of Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

November 4th 2022

ON SEPTEMBER 11, 2022, OncLive® brought together medical oncologists who specialize in the treatment of non–small cell lung cancer (NSCLC). Moderated by Grace K. Dy, MD, the objectives of the workshop were to evaluate the potential role and impact of new antibody-drug conjugates (ADCs) in the treatment of patients with NSCLC.

Targeted Therapies and Expanded NGS Access Improve Decision Making in Lung Cancer

November 3rd 2022

Melissa L. Johnson, MD, shares key insights from the meeting, including pertinent findings in KRAS G12C¬–mutated NSCLC from the phase 3 CodeBreak 200 study and positive findings with atezolizumab in platinum-ineligible patients with NSCLC.

SRF388 Monotherapy Generates Responses in Locally Advanced/Metastatic NSCLC

November 3rd 2022

SRF388 elicited responses in pretreated patients with locally advanced or metastatic non–small cell lung cancer.

NSCLC Molecular Testing Recommendations for Community Hospitals

November 2nd 2022

Recommendations for community hospitals and physicians on the critically necessary molecular tests needed for patients with NSCLC.

Adjuvant Therapy in EGFR-Mutated NSCLC

November 2nd 2022

Drs Spicer and Sabari explain if and when they test patients with NSCLC for EGFR mutations after surgical resection.

POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

November 2nd 2022

Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.